Deltagen Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2012. For the quarter, the company consolidated revenues totaled was $133,000. The revenues in the fourth quarter and in 2012 were attributable to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the company's DeltaOne program. The company's consolidated revenues for the three months ended December 31, 2012 included $88,000 in revenues of Xenopharm Inc. Consolidated net losses before provision for income taxes for the three months ended December 31, 2012 were $677,000 million. Loss from operations was $98,000 for the three months ended December 31, 2012. Net loss was $677,000 for the three months ended December 31, 2012.

For the year, the company reported consolidated revenue of $1,054,000. The revenues in the fourth quarter and in 2012 were attributable to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the company's DeltaOne program. The company's consolidated revenues for the year ended December 31, 2012 included $142,000 in revenues of Xenopharm Inc. Consolidated net losses before provision for income taxes for the year ended December 31, 2012 were $1,165,000. Loss from operations was $53,000 for the year ended December 31, 2012. Net loss was $1,165,000 for the year ended December 31, 2012. These consolidated net losses included recognized net losses of $0.579 million and $1.113 million, respectively, or 43.8% of Benten BioServices' net operating losses, which was accounted for using the equity method of accounting.